Ratings Bayer AG

Equities

BAYN

DE000BAY0017

Market Closed - Xetra 12:35:24 2024-03-18 pm EDT 5-day change 1st Jan Change
26.22 EUR -0.08% Intraday chart for Bayer AG -2.26% -22.05%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • Its low valuation, with P/E ratio at 11.02 and 7.36 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company appears to be poorly valued given its net asset value.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • One of the major weak points of the company is its financial situation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
-22.05% 28.06B
B-
+30.83% 679B
C+
+30.96% 589B
B
+0.01% 381B
C+
+15.18% 314B
C+
+11.39% 308B
B-
+0.78% 212B
B-
-6.09% 210B
A+
-2.92% 203B
B+
-3.72% 158B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes